Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIB: Pembrolizumab in Neoadjuvant TNBC
NCT03289819Phase 2Completed
- Sponsor
- Institut Frauengesundheit
- Start
- Mar 2018
- Primary completion
- Aug 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Institut Frauengesundheit. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03289819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289819.